CrannMed and the EIC Accelerator: Knee Pain Beads, Funded Twice

In knee osteoarthritis, inflamed tissue grows new small blood vessels, which are thought to feed the pain. Genicular artery embolisation blocks them with tiny particles delivered through a catheter. CrannMed, a Galway company incorporated in 2018, makes SakuraBead: resorbable microspheres that, according to the company, block the vessels over about five days and then dissolve, leaving nothing permanent behind.

The European Innovation Council has funded CrannMed twice. In 2021 it granted €2,488,572.80 for a project the company said would fund "a pivotal clinical trial, CE Mark approval and FDA clearance" within two years. In February 2026 it awarded another €12.5 million. Between the two, the company moved from bench tests to a randomised trial in the US and elsewhere. The approvals the first award was meant to deliver have not arrived.

Where CrannMed Stands Today

CrannMed's randomised trial is the key to everything. According to ClinicalTrials.gov, the SURE study compares SakuraBead embolisation with a corticosteroid injection in about 89 patients at sites in the US, the UK, Georgia and Uzbekistan. It began in November 2024, was no longer recruiting in March 2026, and has an estimated primary completion date of October 2026. The US Centers for Medicare & Medicaid Services lists the study's investigational device exemption as approved on 17 April 2025.

In February 2026, Silicon Republic and Horizon Europe Ireland reported the second EIC award: €12.5 million in two phases, €2.5 million to extend the technology to other chronic inflammatory pain, such as hand osteoarthritis and plantar fasciitis, and €10 million for commercialisation in Europe and the US. The company said it expected SakuraBead on the market by the end of 2026.

The Technology: Beads That Dissolve

CrannMed's pitch is a bead that does its job and disappears. The company describes 200µm particles made from naturally occurring biocompatible materials, delivered through a microcatheter designed for the small, winding vessels around the knee. The CORDIS report presents it as a way to reduce pain without leaving a permanent foreign object, for a condition it says affects 30 million people in the EU and US.

What the First EIC Project Promised, and What CORDIS Shows

When the first award was announced in October 2021, CrannMed said the two-year project would fund a pivotal trial, CE marking and FDA clearance. The project ran from May 2022 to November 2024. Its CORDIS report describes bench and preclinical testing, a Class 8 cleanroom, design testing that showed the device's "readiness for human evaluation", international patent applications, and work towards US approval and the CE mark. The pivotal trial started in the month the project ended.

1. A finished, tested deviceDeliveredDesign testing complete and a cleanroom built, per CORDIS.
2. Pivotal clinical trialStarted lateSURE began in November 2024; results due after October 2026.
3. CE markingNot achievedNone announced by September 2026.
4. FDA clearanceNot achievedInvestigational exemption only.

What Has Happened Since the First Award

The early human data come from the company. In December 2023 it reported three patients treated, all with significant pain reduction and discharged within 24 hours. Its clinical results page describes a 15-patient pilot presented at the CIRSE conference in September 2024. We found no peer-reviewed publication of either.

The Money

CrannMed announced its first award as €3.5 million, while CORDIS shows a grant of €2.49 million; the company did not break the figure down. The Irish register via SoloCheck lists 20 shareholders. We found no announced private funding round with an amount. The second EIC award's €10 million phase 2 is tied to commercialisation.

Why Europe Should Care

CORDIS puts knee osteoarthritis at 30 million people in the EU and US. A resorbable embolic made in Ireland would give European clinicians a domestic product, although most of its pivotal trial sites are in the US. The EIC has now bet on it twice, with the second bet five times larger than the first.

The Verdict

CrannMed has not been asked for comment for this article. It is based entirely on public records, company statements, clinical registry data and EU project data, linked throughout.